Invasight is a clinical biotech company that focused on revolutionizing cell invasion research.
Invasight has raised $4.6M in total funding. The most recent round was Seed. The last funding was announced in June 2022.
Invasight's investors include HTGF (High-Tech Gruenderfonds), Verve Ventures, Zürcher Kantonal Bank, Venture Kick, Wille Finance.
Invasight is headquartered in Zürich, Switzerland.
Invasight is a clinical biotech company that focused on revolutionizing cell invasion research.
Invasight is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Invasight — Funding & Investors." VCBacked, June 7, 2022, https://www.vcbacked.co/company/invasight. Accessed August 15, 2026.
VCBacked. (2022). Invasight — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/invasight
{{cite web |title=Invasight — Funding & Investors |url=https://www.vcbacked.co/company/invasight |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated